Systematic review and meta-analysis on the prophylactic role of non-steroidal anti-inflammatory drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis

Table 1 Characteristics of included trials

Ref.	Year	Country	Time of administration	Route	Dose	Type of NSAIDs used
Cheon et al[22]	2007	United States	Before ERCP	Oral	50 mg	Diclofenac
Döbrönte et al[23]	2012	Hungary	Before ERCP	Rectal	100 mg	Indomethacin
Döbrönte et al[24]	2014	Hungary	Before ERCP	Rectal	100 mg	Indomethacin
Elmunzer et al[25]	2012	United States	After ERCP	Rectal	100 mg	Indomethacin
Khoshbaten et al[26]	2008	Iran	After ERCP	Rectal	100 mg	Diclofenac
Montaño Loza et al[27]	2006	Mexico	Before ERCP	Rectal	100 mg	Indomethacin
Montaño Loza et al[28]	2007	Mexico	Before ERCP	Rectal	100 mg	Indomethacin
Murray et al[29]	2003	United Kingdom	After ERCP	Rectal	100 mg	Diclofenac
Otsuka et al[30]	2012	Japan	Before ERCP	Rectal	50 mg	Diclofenac
Park et al[31]	2014	United States South Korea	After ERCP	Intramuscular	90 mg	Diclofenac
Senol et al[32]	2009	Turkey	After ERCP	Intravenous infusion	75 mg	Diclofenac
Sotoudehmanesh et al[33]	2007	Iran	Before ERCP	Rectal	100 mg	Indomethacin
Zhao et al[34]	2014	China	After ERCP	Intramuscular	75 mg	Diclofenac

NSAIDs: Non-steroidal anti-inflammatory drugs; ERCP: Endoscopic retrograde cholangio-pancreaticography.